It was reported on Tuesday that CATO SMS, a company focused on specialised clinical research solutions, has acquired United States-based Array Biostatistics.
This move is to help CATO SMS expand its full-service biostatistical consulting, analysis and programming capabilities. CATO SMS is to concentrate on building its team of senior biostaticians and statistical programmers as part of its expansion plans.
Array will continue to be led by Sandy Ferber, chief executive officer of Array. Ferber will also lead CATO SMS' overall biometrics offering.
Physiomics secures follow-on UK contract for Phase 2 study support
Ascletis reports positive US Phase I data for oral IL-17 inhibitor ASC50
Dimerix completes adult recruitment in ACTION3 Phase 3 DMX-200 trial
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Vanda files FDA Biologics License Application for imsidolimab in generalized pustular psoriasis
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion
Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
OTR Therapeutics agrees strategic collaboration and licence agreement with Zealand Pharma A/S
Privo Technologies doses first patient in first-in-human clinical trial of PRV131